Relates to Heterocyclic compounds of formula (i) where a is B is phenyl, phenyl Pyridine or pyrimidine Ring R1 and R2 are each h, o or Halogen R3, R4 and R5 are each H or alkyl (C1 - C6), Oh, heterocicloalquil - (CH2) - Oh among others, where n is 1 to 3 R6 is H or alkyl or alkyl (C1 - C6) (C1 - C6) X is n or C a is CH or Covalent bonding.Preferred compounds are: 4 - chlorine - 3 - [2 - (3 - ilamino pyridin -) - [1,2,4] triazolo [1,5-a] pyridin - 6 - yl] - phenol 4 - Chloro - 3 - [2 - (5 - ilamino - pyrimidin-2-yl) - [1,2,4 triazolo [1,5-a] - il - 6] pyridin-3] - phenol 4 - Chloro - 3 - [2 - (5 - Hydroxymethyl - pyridin - 3 - ilamino) - [1,2,4] triazolo [1,5-a] pyridin - 6 - yl] - phenol among others. It also relates to a Pharmaceutical composition.These compounds are inhibitors of SRC kinase being useful in the treatment of retinal edema, Macular Degeneration, Diabetic RetinopathySE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE A ES FENILO B ES FENILO, PIRIDINA O PIRIMIDINA R1 Y R2 SON CADA UNO H, OH O HALOGENO R3, R4 Y R5 SON CADA UNO H, O-ALQUILO(C1-C6), OH, HETEROCICLOALQUIL-(CH2)n-OH, ENTRE OTROS, EN DONDE n ES DE 1 A 3 R6 ES H, O-ALQUILO(C1-C6) O ALQUILO(C1-C6) X ES N O C Y ES CH O UN ENLACE COVALENTE. SON COMPUESTOS PREFERIDOS: 4-CLORO-3-[2-(PIRIDIN-3-ILAMINO)-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-6-IL]-FENOL 4-CLORO-3-[2-(PIRIMIDIN-5-ILAMINO)-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-6-IL]-FENOL 4-CLORO-3-[2-(5-HIDROXIMETIL-PIRIDIN-3-ILAMINO)-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-6-IL]-FENOL ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASA Src SIENDO UTILES EN EL TRATAMIENTO DE EDEMA RETINIANO, DEGENERACION MACULAR, RETINOPATIA DIABETICA
